ABSTRACT
INTRODUCTION
The antiphospholipid (aPL) syndrome (APS), an autoimmune thrombophilic disorder, that is believed to affect ~10% of patients who have vascular thrombosis 1 and ~20% of patients with recurrent spontaneous pregnancy losses. 2 Prevention of recurrent thrombosis in APS requires long term anticoagulant therapy, 3 a treatment associated with the risk of hemorrhagic complications. 3 The elucidation of specific mechanisms by which antiphospholipid antibodies may promote thrombosis may be useful for targeting treatment to earlier steps in the APS disease process.
The aPL antibody-mediated disruption of the annexin A5 (AnxA5) anticoagulant shield is a thrombogenic mechanism for APS for which substantial evidence has accumulated. 4 AnxA5, which had been isolated from tissues as a vascular anticoagulant protein 5 and as a placental anticoagulant protein, 6 exhibits high affinity for anionic phospholipids. 5;6 Its potent anticoagulant properties result from its forming 2-dimensional crystals over phospholipid bilayers, 7 thereby shielding them from availability for critical coagulation enzyme reactions. 5 aPL antibodies interfere with AnxA5 binding, [8] [9] [10] [11] and with its ordered crystallization, 12 thereby accelerating coagulation reactions. 8;12 This aPL antibody-mediated reduction of AnxA5 has also been demonstrated on placental trophoblasts, [13] [14] [15] endothelial cells 14;16 and platelets. 8;11 The interference with AnxA5 anticoagulant activity has been correlated with aPL antibodies that recognize a specific epitope on domain I of ß2-glycoprotein I (ß2GPI) 17 -considered to be the central protein recognized by aPL antibodies 18 -that is associated with increased risk of thrombosis. Assays of blood samples for AnxA5 binding 8;9;11;19;20 and anticoagulant activity 8;20;21 For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From showed significant reductions in patients with APS and thrombosis,) and also in patients with histories for recurrent pregnancy losses. 22 Hydroxychloroquine (HCQ) is a synthetic antimalarial compound that has proven to be an effective immunosuppressive treatment of systemic lupus erythematosus (SLE). [23] [24] [25] [26] A reduction in the frequency of thrombosis among SLE patients treated with HCQ was first suggested over 20 years ago 27 and buttressed by further evidence in patients with SLE [28] [29] [30] and APS. 30;31 The
Hopkins Lupus Cohort reported that the presence of aPL antibodies are independent predictors of thrombosis in SLE, and that treatment of SLE patients with HCQ was associated with a reduced risk of thrombosis. 28 A cross-sectional study that compared aPL antibody-positive patients with thrombosis to a group of patients having the antibodies but who did not have thrombotic histories indicated that HCQ may be protective against thrombosis. 31 An observational study of a prospective cohort of SLE patients reported a strong and independent antithrombotic effect of antimalarials in a time-varying Cox model. 32 Another prospective study of patients in a lupus clinic who did not have a prior history for thrombotic manifestations indicated that aPL positivity was a risk factor for thrombosis with a hazard ratio (HR) of 5.87 for subsequent thrombosis compared to the aPL negative SLE patients, and that treatment with HCQ reduced the HR for thrombosis/month to 0.99; 30 interestingly, the risk of thrombosis was also reduced in the aPLnegative group. A recent systematic review of the literature on antimalarial treatment in SLE concluded that there was moderate evidence for protection against thrombosis. 33 The drug significantly reduced the extent of experimentally provoked thrombosis in an animal model of APS, 34 and also reversed aPL-mediated platelet activation. 35 We recently demonstrated that HCQ reduces the binding of aPL IgG-ß2GPI complexes to phospholipid bilayers, and through 36 These effects of HCQ prompted us to investigate whether the drug might protect the binding of AnxA5 from disruption by aPL IgG-ß2GPI. We investigated this question with purified proteins and phospholipids, with cultured human umbilical-vein endothelial cells (HUVECs), with a cultured syncytialized trophoblast cell (STC) line, and with human APS plasma samples.
MATERIALS AND METHODS

Reagents
The research protocol was approved by the institutional review board of Montefiore Medical Center, which granted permission for the use of excess plasmas from APS patients that had been obtained from clinical assays or plasmapheresate discards, and were anonymized. Polyclonal IgG antibodies were isolated with protein G from citrated plasma of three well characterized patients with severe APS and 3 disease-free controls, as previously described, 14 The 3 APS IgGs, at the concentration that was used for the experiments described below -i.e. 0.5 mg/ml -were assayed for anticardiolipin IgG, anti-β2GPI IgG, and lupus anticoagulant with standard clinical laboratory tests. All had elevated anticardiolipin IgG levels (61-84 GPL units), and elevated anti-β2GPI IgG levels (60-155GPL units); 2 of the 3 IgGs had positive lupus anticoagulant tests by standard dilute Russell viper venom time assays performed with mixing and confirmatory steps. A human aPL monoclonal IgG antibody (mAb), designated IS4, was purified as previously described. 37 This well characterized mAb was selected because it is purified and highly specific, qualities necessary for high resolution of AFM imaging. IS4 recognizes ß2GPI and anionic 
Effect of HCQ on AnxA5 Binding
Phospholipid bilayers composed of 30% 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (PS) and 70% 1,2-dioleoyl-sn-glycero-3-phosphocholine (PC) (Avanti Polar-lipids, Inc., Alabaster AL)
were formed on reflective silicon slides as previously described 12 and transferred to cuvettes containing 1 mL of HBS supplemented with 0.05% bovine serum albumin (BSA) and 1.25 mM calcium for studies described below.
We performed the following experiment to determine whether HCQ might modify the effects of To investigate whether HCQ might affect the affinity of AnxA5 itself for the phospholipid bilayers, HCQ (1 mg/mL) or buffer control was added to the bilayer; aliquots of unlabeled AnxA5 were added serially (up to 10 µg/mL), after the prior addition had reach equilibrium.
Based on the measured free AnxA5 and the total amount of AnxA5 added to the bilayer, traditional graphs plotting phospholipid-bound AnxA5 versus free AnxA5 were generated. Using
SigmaPlot software (SPSS, Chicago, IL), Langmuir isotherms were fit simultaneously to binding data to determine a Kd in the absence of HCQ, a Kd in the presence of 1 mg/mL HCQ, and a maximum binding capacity independent of HCQ.
Human Umbilical Vein Endothelial Cell Cultures
Tissue culture materials and reagents were obtained from Life Technologies, Inc (Gaithersburg, MD) unless otherwise specified. Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords and the second passage of primary HUVECs was immortalized by overexpression of murine telomerase reverse transcriptase. 39 The cells were maintained in culture medium consisting of Dulbecco's modified eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 50 U/mL of the penicillin-streptomycin antibiotics for and plasma coagulation assays were performed as described below.
Syncytialized Trophoblast Cell Line Cultures
A human trophoblast cell line (BeWo) obtained from the American Type Culture Collection (ATCC, Rockville, MD), was used for these experiments, as it was previously shown to respond to aPL IgG in an manner equivalent to primary syncytialized placental trophoblasts. 14;15 Cells maintained in 90% Ham's F12K medium with 2 mM glutamine, 1.5 g/L sodium bicarbonate and 10% FBS were plated at densities of ~9 x 10 4 cells/well in 96-well culture plates. 14 After 5 hours they were syncytialized via addition of forskolin (20 µmol/L, Sigma-Aldrich Corporation) and maintained with daily feeding for up to 72 hours. 15 These syncytialized trophoblast cells (STCs)
were rinsed with HBS-CaCl 2 and then treated with aPL or control IgG, in the absence or presence of HCQ, as described above for HUVECs. Trypan-blue exclusion studies demonstrated that the IgG-treated STCs were at least 95% viable. Measurements of IgG and AnxA5 on cell membranes and plasma coagulation assays were performed as described below.
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Effects of HCQ on Cell Surface IgG and AnxA5 Levels
To determine the quantities of IgG bound to the cell surfaces, aPL and control IgG-treated HUVECs or SCTS, in the presence and absence of HCQ at 2 concentrations (1ug/ml and 1 mg/ml), were rinsed with HBS, incubated with HRP-conjugated goat antihuman IgG (Corgenix Inc, Colorado) for 60 minutes at 4°C, rinsed twice with HBS and incubated with tetramethyl benzidine substrate for 30 minutes at room temperature. The reactions were stopped by addition of sulfuric acid. The optical absorbances were measured at 450 nm with a reference wavelength of 650 nm; results were read against a standard curve using phosphatidylserine-coated microtiter plates (REAADS Medical Products, Inc., Westminster, CO) and reported as arbitrary aPS IgG units per well (AU/well).
Cell surface AnxA5 levels were determined after the IgG-treated HUVECS and STCs were rinsed with HBS-CaCl 2 , (in order to prevent dissociation of endogenous AnxA5) as previously described.
14
Effects of HCQ on Cell Surface Plasma Coagulation
Studies were performed with cultured HUVECs and STCs, as previously described, 14 with minor modifications. Briefly, cells were grown to confluence in 96-well culture plates, rinsed with HBS-CaCl 2 , and incubated at 4°C with aPL or control IgGs (0.5 mg/mL) in culture media with or without HCQ, as described above. After one wash with HBS-CaCl 2 , the cells were overlaid with citrated normal pooled plasma (200 µL/well), which was recalcified with 20 mM CaCl 2 .
The culture plates were placed in a kinetic microtiter-plate reader (SPECTRAmax Plus 384;
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Molecular Devices, Sunnyvale, CA) at 37°C and the times until fibrin formation were measured; fibrin formation was detected by an increase of optical density to 0.100 at 405 nm.
Effects of HCQ on Annexin A5 Anticoagulant Activity
Excess citrated plasmas from ten patients that had been used for clinical assays and anonymized, were stored at -80°C and used for these assays. The plasma samples were selected on the basis of positive assays for annexin A5 resistance that were performed in the Hematology Laboratory of Montefiore Medical Center, as described in the paragraph below. The patients included 7 women and 3 men who ranged in age from 17 to 54 years, with the following clinical aspects (total more than 10 because of patients with more than one manifestation): one patient with catastrophic APS (CAPS) who also had DVT, four other patients with venous thrombosis and/or pulmonary embolism, two patients with arterial thrombosis, three patients with recurrent spontaneous miscarriages, one patient with preeclampsia, and one patient with ulcerative colitis. Two of the patients had SLE and were therefore defined as having secondary APS. All had elevated anticardiolipin and anti-ß2GPI IgG antibodies along with positive LA by international consensus criteria. 40 A modified 2-stage method was used to determine the effects of HCQ on AnxA5 anticoagulant activity of these plasmas as previously described. 17 AnxA5 anticoagulant ratio = (coagulation time in the presence of AnxA5/coagulation time in the absence of AnxA5) x 100%.
Atomic Force Microscopy Imaging Studies
AFM experiments were performed to visualize the structures formed by AnxA5, ß2GPI and aPL mAb, IS4-on phospholipid bilayers (30% PS and 70% PC), as previously described. 12;36 Two types of experiments, referred to as endpoint and dynamic imaging experiments, were performed. In endpoint imaging experiments, 12 the proteins AnxA5 (60 µg/ml), ß2GPI (10 µg/mL) and IS4 (10 µg/mL) in 150 µl of HBS containing 1.25 mM CaCl 2 (HBS-CaCl 2 ) were incubated with the bilayer for 2.5 hours in the absence or presence of HCQ (1 mg/ml), after which imaging was performed. The dynamic imaging experiments 12 were performed to elucidate the sequential development of structures observed in the endpoint experiments. For these studies, ß2GPI (10 µg/mL) in 150 µl of HBS with 1.25 mM CaCl 2 was first added to the bilayers and incubated overnight at 4 o C to allow the ß2GPI clusters to form, as previously described.
36;41
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The next morning, continuous imaging of the lipid bilayer was initiated and AnxA5 (60 µg/ml) and IS4 (10 µg/mL) were added sequentially, in the absence or presence of HCQ (1 mg/ml). EDTA (2.2 mM) was added at the end of experiments to confirm the dissociation of AnxA5, for which binding is calcium dependent. The order of addition was also modified wherein IS4 (10 µg/mL) was first added to allow immune complexes to form after which HCQ (1 mg/ml) and AnxA5 (60 µg/ml) were added, followed, at the end of the experiment, by EDTA (2.2 mM).
Adsorption of proteins was observed using "tapping mode" imaging with a Digital Instruments BioScope (Nanoscope IIIa controller; Veeco, Santa Barbara, CA) employing either oxide- 
Statistical Analysis
Results of measurements obtained in the absence and presence of HCQ -i.e. IgG levels, AnxA5 levels, plasma coagulation times and AnxA5 anticoagulant ratios -were compared using paired two-tailed t-test (Instat program, Graphpad, San Diego, CA). Differences between the treatments of aPL versus control groups were analyzed using unpaired two-tailed t-tests. P-values of less than 0.05 were considered statistically significant.
RESULTS
Effects of HCQ on aPL IgG-mediated Reduction of AnxA5 Binding
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We first investigated whether HCQ might modify the reduction of AnxA5 binding that is induced by aPL IgGs. In accordance with previous results, 8-10;12-14;20;42 we found that aPL IgGs, in the absence of HCQ, significantly reduced the binding of AnxA5 to phospholipids ( Figure   1A ). In the presence of HCQ (1 mg/mL), binding of AnxA5 was restored to the same levels observed with control IgGs ( Figure 1B) . The acceleration of AnxA5 binding by HCQ with control IgG -i.e. even in the absence of aPL IgG -was a reproducible finding.
Studies of HCQ interaction with Annexin A5
We then investigated whether the restoration of AnxA5 binding by HCQ might be explained by 
Studies with Cultured Cell Lines
Cultured HUVECs and STCs that were exposed to aPL IgGs bound significantly more IgG than cells exposed to control IgGs ( Figure 3A) . HCQ significantly reduced aPL IgG binding to levels similar to control IgGs. Also, aPL IgG-treated cells had significantly less AnxA5 bound to their surfaces than control IgG-treated cells ( Figure 3B ), as previously reported. 14 Addition of HCQ significantly increased the levels of AnxA5 on aPL IgG-treated HUVECS and STCs to similar levels observed with control IgG ( Figure 3B ). We then investigated whether the HCQ-mediated increase of cell surface AnxA5 might correlate with prolongation of the coagulation times of plasmas exposed to these cells. As previously reported, 14 the coagulation times of plasma overlaid on aPL IgG-exposed cells were significantly accelerated compared to control IgGs in the absence of HCQ ( Figure 3C ). However, the addition of HCQ reversed the acceleration, and prolonged the coagulation times to levels that were not significantly different than control IgGs ( Figure 3C ). Also, in the presence of HCQ, there were no significant differences in IgG levels,
AnxA5 levels, or coagulation times between aPL IgG-treated cells and the control IgG-treated cells (data not shown).
Effect of HCQ on Annexin A5 Anticoagulant Ratio
HCQ significantly increased the mean AnxA5 anticoagulant ratio of APS plasmas (Figure 4 ).
Nine out of the 10 plasmas that were tested demonstrated this effect.
Atomic Force Microscopy Imaging Studies
In the absence of HCQ, the AnxA5 crystalline array was markedly disrupted by aPL mAb-ß2GPI immune complexes ( Figure 5A ), as previously described. 7;12 Addition of HCQ (1 mg/mL) resulted in coverage of the entire surface with cobblestone-like patches of AnxA5 around and over the former aPL mAb-ß2GPI complexes ( Figure 5B ). HCQ had no discernible direct effect upon the phospholipid bilayer itself -i.e. in the absence of added proteins, there were no changes in the appearance of the PS/PC surface (data not shown).
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To observe the sequential formation of the AnxA5 patches shown above, experiments were performed with step-wise additions of β 2GPI, aPL mAb, HCQ and AnxA5 ( Figure 6A-D) .
Addition of β 2GPI resulted in formation of clusters ( Figure 6A ), as previously described.
36;41
The subsequent addition of the aPL mAb resulted in formation of immune complexes that increased the heights and sizes of these clusters ( Figure 6B ), as previously described. 36 Subsequent addition of HCQ and AnxA5 resulted in erosion of the immune complexes ( Figure   6C ) and the growth of patches of AnxA5 over the former aPL IgG-β2GPI clusters ( Figure 6D ).
These patches assumed cobblestone-like appearances that were identical to those observed in the endpoint experiments shown in Figure 5B .
The sequential formation of the AnxA5 patches was further visualized by step-wise additions of Figure 7D ). However, when HCQ was present in the system, the coalescence of growing AnxA5 crystals from the initial nucleation sites into the primary layer of the 2-dimensional crystal ( Figure 7G ) was followed by the formation of secondary layers of AnxA5 crystals over β 2GPI clusters, that grew progressively ( Figure 7H) and had a similar morphologic appearance to the AnxA5 patches that were observed in the Figure 7B ). The identity of the secondary layers of protein as AnxA5 was confirmed by their dissociation after addition of EDTA (data not shown).
DISCUSSION
The results of prior clinical studies, indicating that HCQ may have a beneficial effect in reducing thrombosis in SLE and APS, [27] [28] [29] [30] [31] [32] [33] along with evidence from an animal model, 34 previously led us to investigate the direct effects of HCQ on aPL IgG-ß2GPI complexes. 36 The findings that HCQ can disintegrate aPL IgG-ß2GPI complexes and reduce the binding of the individual proteins as well as the complexes to phospholipid bilayers, 36 prompted us to now ask whether the drug might also protect AnxA5 from displacement by aPL antibodies.
The results of the present study showed that HCQ restored the binding of AnxA5 to phospholipids to the levels of control IgGs ( Figure 1A and B). We performed formal binding studies to address the question of whether the drug might increase the affinity of AnxA5 for the phospholipid bilayer and found this not to be the case. Rather, the drug induced a modest, but statistically significant, reduction in the affinity of AnxA5 (Figure 2) , while increasing the binding of the protein in the presence of aPL IgGs (Fig 1B) . It is interesting that the binding of AnxA5 was reproducibly accelerated in the presence of HCQ even in the presence of the control IgG (Fig 1B) . The mechanism for the latter observation is not yet clear and is a subject for additional investigation in our laboratory.
The HCQ-mediated restoration of AnxA5 was not limited to phospholipid bilayers, but was also evident on cultured HUVECs and STCs, where the drug reversed the aPL IgG-mediated increase in cell surface IgG levels ( Figure 3A) , reversed the aPL IgG-mediated decreases in cell surface AnxA5 levels ( Figure 3B) , and also prolonged the coagulation times of plasmas overlaid on the cells ( Figure 3C ).
To obtain an indication of whether the results of these phospholipid binding studies, cell culture experiments with polyclonal IgG fractions and AFM imaging studies with aPL mAb might be generalizable to patients with APS, we examined the effect of HCQ on AnxA5 anticoagulant ratios of APS patients. This assay for resistance to AnxA5 anticoagulant activity is abnormal in patients with APS 17;20;21 and in patients with recurrent miscarriages. 22 The in vitro addition of HCQ increased the AnxA5 anticoagulant ratios of 9 of the 10 patients tested (Figure 4 ).
The AFM imaging experiments offered an interesting view on the possible mechanism for this HCQ effect. In the presence of the drug, AnxA5 formed oval patches around and over the aPL IgG-ß2GPI complexes, each of which bordered adjoining patches, resulting in a cobblestone appearance that covered what had previously been a highly irregular surface ( Figure 5 ).
Sequential experiments indicated that following the formation of the initial 2-dimensional
AnxA5 crystals over the phospholipid bilayer, HCQ could promote the formation of a second layer of AnxA5 crystal whose nucleation sites originate around and over ß2GPI clusters themselves. These second layers crystallized outward in a circular manner and extended beyond the borders of the clusters over the primary layer of AnxA5. The precise mechanism of this reproducible and fascinating effect, as well as modifications of the orders of addition, and the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From effects of epitope specific antibodies and structural modifications of the involved proteins are currently a focus of research in our laboratory.
We have previously shown that HCQ unequivocally disrupts aPL IgG-ß2GPI complexes by 4 types of methods including ellipsometry experiments, immunoassays on microtiter plates, immunoassays on cultured cells, and AFM imaging. 36 This effect was also evident in the current cell culture experiments and in the AFM sequence shown in Figure 6 . The disruption was not evident in the AFM sequence shown in Figure 7 because of the sequence of addition of reagents -i.e. the AnxA5 was allowed to crystallize around the β 2GPI complexes prior to addition of the aPL mAb.
Although these studies suggest that HCQ may exert a direct therapeutic effect in reducing thrombosis, definitive conclusions will require appropriately designed prospective randomized clinical trials. Since there are also significant data indicating that AnxA5 is a placental anticoagulant protein that may play a thrombomodulatory role in maintaining the flow of maternal blood through the placental circulation, 13;43;44 it would be interesting to learn whether HCQ might be beneficial in treating women with the pregnancy complications of APS. There have been several reports -most recently reference 45 -on the efficacy of this drug for treating pregnant women with SLE and regarding the apparent absence of fetal toxicity. The more than half century of experience with this drug for treating malaria 46 and SLE, 47 its established profile with respect to adverse effects, toxicities and drug interactions, and the absence of hemorrhagic risks are some of the factors that would favor its being evaluated for treatment of APS in prospective randomized clinical trials.
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The HCQ concentration of 1 µg/mL and greater was used in the cell culture studies since that was reported to be the mean blood concentration of drug in SLE patients who comply with treatment. 48 A concentration of 1 mg/mL was used for the binding and imaging studies with purified proteins and phospholipid bilayers since previous studies had shown the disruption of aPL-ß2GPI bilayers to be most evident at that concentration. 36 The actual concentrations of HCQ in vivo in the microenvironment that is the presumptive site of action for this mechanism -i.e.
apical surfaces of cell membranes -is not known.
aPL antibodies appear to be highly heterogeneous. Although there is a general consensus that the thrombogenic mechanism(s) of APS involve autoantibody recognition of phospholipid binding proteins, particularly ß2GPI, the specific mechanism(s) that are operative in vivo have not been established, and are likely to be complex and multifactorial. It is very possible that the HCQmediated disruption of aPL IgG-β2GPI complexes may also impact on other mechanisms that involve the aPL-β2GPI interaction, examples of which include the triggering of signaling events that lead to a proadhesive and prothrombotic phenotype, acquired resistance to protein C activation and the activation of complement. 49 We plan to address this question in future studies. In conclusion, these data demonstrate that an antimalarial drug, HCQ, can protect the AnxA5 anticoagulant shield from disruption by aPL antibodies on phospholipid bilayers, on the apical membranes of cultured HUVECS and STCs, and in samples of APS patient plasmas. These results demonstrate that it may be possible to target earlier steps in the APS disease process than those addressed by anticoagulant therapy. Appropriately designed clinical trials will be required to validate this concept.
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In a sequence that included HCQ, (E) addition of ß2GPI to phospholipid bilayers and formation of ß2GPI clusters (marked 1-5) were followed by, (F) addition of HCQ, followed by (G) addition of AnxA5 which at first crystallized from multiple different nucleation sites on the phospholipid bilayer, (H) and then, formed a secondary layer of AnxA5 over the ß2GPI which progressively grew around and over the adjacent primary layer of AnxA5 crystal, leaving none of the surface uncovered by AnxA5.
